Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Brochures & Literature



View Channel


Conferences | Events

Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia – the MIND-MAPS Study

publication date: May 17, 2017
author/source: Imanova

Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding.

imanovaThe funding, from the MRC, is for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme.

Kevin Cox, Imanova’s CEO, commented: “We are delighted to have been awarded strategic funding for the MIND-MAPS programme. We would like to thank the MRC and Dementias Platform UK (DPUK) for supporting the proposal and look forward to engaging more widely with the DPUK Imaging Network.”

MIND-MAPS is a pre-competitive consortium between Imanova, AbbVie, the MRC, the Hamamatsu Photonics PET centre, drawing on the therapy area expertise of the DPUK members.

The aim of the programme is the evaluation of multiple markers of neuropathological changes, in healthy subjects and patients with Alzheimer’s and Parkinson’s disease, to investigate common pathways of neurodegeneration. Well characterised molecular markers of neurodegenerative disease progression promise to accelerate the development of disease modifying treatment by providing objective and sensitive early markers to evaluate novel treatments.

Ilan Rabiner, Chief Medical Officer at Imanova, stated: “This will be the first study evaluating a set of molecular markers within an individual and will provide the tools for early assessment of novel disease modifying treatments, which currently require long and expensive Phase II studies for proof of concept.”

The study team will work closely with the DPUK Imaging Network, a newly established network that links neuroimaging for neurodegenerative disease across eight major UK research institutions (Cambridge, UCL, KCL, Imperial College London, Cardiff, Manchester, Newcastle, and Edinburgh).

more about imanova



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners